Merck’s Cholesterol Pill Delivers ‘Antibody-Like Efficacy’ After Earning FDA Voucher

Merck is eyeing a quick review for its lipid-lowering drug candidate enlicitide, which in December was awarded a Commissioner’s National Priority Voucher.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top